Delivery Order SPE2DB20D2104-SPE2DB21FT95F
- Not listed
- This federal contract award, valued at $3,933.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4558598562 TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC serves...
- This federal contract award, valued at $2,745.46, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with a completion date of December 13, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical....
- This federal contract award, valued at $1,872.64, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999, which serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of...
- This federal contract award, valued at $6,782.62, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with an ultimate completion date of November 20, 2023. The contract is a Delivery Order under a Firm Fixed Price pricing arrangement, with no set-aside designation indicated. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award, valued at $7,537.58, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a pharmaceutical distribution company and subsidiary of Cencora, Inc. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, which is a vaccine product. The contract has an ultimate completion date of October 24, 2023 and is a firm fixed-price delivery order. The contract award is not associated with a set-aside designation, indicating it was...
- This federal contract award, valued at $2,589.87, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, to support military healthcare programs. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $37,963.28 delivery order contract is for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract has a firm fixed-price pricing type and an ultimate completion date of October 24, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,000.85 delivery order contract is for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract is a firm fixed-price agreement with an ultimate completion date of August 11, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $34,282.82 firm fixed-price delivery order is for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The award has an ultimate completion date of March 11, 2024. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., maintains a significant $999,999,999 Indefinite Delivery...
- This federal contract award, valued at $3,783.07, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with a completion date of May 15, 2025. The contract type is Delivery Order with a Firm Fixed Price pricing structure, and it is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB21FT95FDelivery Order
This federal contract award, valued at $3,837.55, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with an ultimate completion date of September 16, 2021. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen Drug Corp holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. The contract award did not have a set-aside designation, indicating it was issued through full and open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 9/15/21 |